N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 / Phase 3 ClinicalTrials.gov

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

Sponsor: Peptilogics • ClinicalTrials.gov ID: NCT07214311

Registry updated: 2026-10-22
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.

Interventions

  • PLG0206 (Drug)
    PLG0206 Solution
  • Placebo (Drug)
    Placebo

Eligibility criteria

Inclusion Criteria: * Male or female participants age between 18 and \<86 years * Able to provide informed consent, geographically stable, and able to comply with the required follow-up visits * Suspected or confirmed PJI of the knee * Well-fixed and positioned prosthesis and good condition of surrounding soft tissue (no sinus tract) * A single DAIR procedure is indicated as treatment of PJI * Agree to use contraceptives if of childbearing potential Exclusion Criteria: * Loose prosthesis or surgical treatment planned for removal of well-fixed, nonmodular implants * Anticipated to require antibiotic therapy for \>6 months after DAIR procedure * Infection spread beyond the affected knee joint (e.g., osteomyelitis) * History of a prior confirmed PJI of the affected knee, including prior DAIR or revision surgery for PJI * Two or more prior revisions in the affected joint for reasons other than infection * Epithelialized sinus tract with evidence of communication to the joint or visualization of prosthesis * Diabetes mellitus and with an A1c ≥9% within 3 months, according to medical history * History of malignant disease and having received immunosuppressive therapy, radiation therapy, or chemotherapy within the past year * Known immunodeficiency (e.g., splenectomy; sickle cell anemia; human immunodeficiency virus \[HIV\] with recent CD4 count \<200 cells/mm3; or primary humoral, bone marrow, or other transplantation)

Conditions

Prosthetic-joint Infection

Locations

  • Clinical Trial Site — Sarasota, Florida, United States
  • Clinical Trial Site — Tamarac, Florida, United States
  • Clinical Trial Site — Shreveport, Louisiana, United States
  • Clinical Trial Site — Baltimore, Maryland, United States
  • Clinical Trial Site — Boston, Massachusetts, United States
  • Clinical Trial Site — New York, New York, United States
  • Clinical Trial Site — Leland, North Carolina, United States
  • Clinical Trial Site — Cincinnati, Ohio, United States
  • Clinical Trial Site — Cleveland, Ohio, United States
  • Clinical Trial Site — Columbus, Ohio, United States
  • Clinical Trial Site — Pittsburgh, Pennsylvania, United States
  • Clinical Trial Site — Dallas, Texas, United States
  • Clinical Trial Site — Edinburg, Texas, United States
  • Clinical Trial Site — Katy, Texas, United States
  • Clinical Trial Site — Salt Lake City, Utah, United States
  • Clinical Trial Site — Morgantown, West Virginia, United States
  • Clinical Trial Site — Cambridge, Cambridgeshire, United Kingdom
  • Clinical Trial Site — Edinburgh, Lothian, United Kingdom
  • Clinical Trial Site — Norwich, Norfolk, United Kingdom
  • Clinical Trial Site — Coventry, West Midlands, United Kingdom
  • Clinical Trial Site — Leeds, West Yorkshire, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record